Bliss GVS Pharma (506197) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
20 Nov, 2025Executive summary
Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, following a meeting on July 29, 2025.
Financials prepared per Ind AS and reviewed by statutory auditors with unmodified conclusions.
Financial highlights
Standalone revenue from operations for Q1 FY26 was ₹16,336.43 lakh, up from ₹14,896.29 lakh in Q1 FY25.
Consolidated revenue from operations for Q1 FY26 was ₹20,746.92 lakh, up from ₹18,364.27 lakh in Q1 FY25.
Standalone net profit for Q1 FY26 was ₹2,105.29 lakh, compared to ₹1,145.21 lakh in Q1 FY25.
Consolidated net profit for Q1 FY26 was ₹4,303.79 lakh, compared to ₹2,069.74 lakh in Q1 FY25.
Basic EPS (consolidated) for Q1 FY26 was ₹4.08, up from ₹1.97 in Q1 FY25.
Outlook and guidance
No explicit forward-looking guidance provided, but results reflect continued growth in revenue and profitability year-over-year.
Latest events from Bliss GVS Pharma
- Revenue and net profit rose year-over-year, with EPS at ₹4.08 and new director appointment approved.506197
Q1 26/27 - Revenue and net profit rose sharply year-over-year, with a ₹1 dividend proposed.506197Q4 25/26
- Q3 FY26 net profit reached ₹2,477.91 lakh; interim dividend of 0.50 paisa per share declared.506197Q3 25/26
- Strong revenue and profit growth, improved cash flow, and key management appointment in H1 FY26.506197Q2 25/26
- Revenue and net profit increased, with new leadership and regulatory fine payment noted.506197Q2 24/25
- Q1 FY25 saw year-over-year growth in revenue and profit, with improved margins and ESOP activity.506197Q1 24/25
- Revenue and net profit rose year-over-year, with key divestment and equity actions approved.506197Q4 24/25
- Quarterly and nine-month profits rose, with ESOP share allotments and subsidiary impairments noted.506197Q3 24/25